Ultragenyx Pharmaceutical (RARE) Receives Consensus Recommendation of “Buy” from Brokerages

Ultragenyx Pharmaceutical (NASDAQ:RARE) has earned an average rating of “Buy” from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $69.13.

Several brokerages have recently weighed in on RARE. ValuEngine upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Robert W. Baird restated a “buy” rating and set a $70.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 23rd. Finally, Piper Jaffray restated an “overweight” rating and set a $67.00 price target on shares of Ultragenyx Pharmaceutical in a report on Thursday, March 22nd.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Trust Advisors LP increased its holdings in Ultragenyx Pharmaceutical by 49.4% in the 4th quarter. First Trust Advisors LP now owns 785,694 shares of the biopharmaceutical company’s stock worth $36,440,000 after buying an additional 259,816 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Ultragenyx Pharmaceutical by 8.7% in the 4th quarter. Alliancebernstein L.P. now owns 700,406 shares of the biopharmaceutical company’s stock worth $32,485,000 after buying an additional 56,106 shares in the last quarter. Fred Alger Management Inc. increased its holdings in Ultragenyx Pharmaceutical by 6.0% in the 4th quarter. Fred Alger Management Inc. now owns 389,236 shares of the biopharmaceutical company’s stock worth $18,053,000 after buying an additional 22,168 shares in the last quarter. Brown Advisory Inc. increased its holdings in Ultragenyx Pharmaceutical by 3.4% in the 4th quarter. Brown Advisory Inc. now owns 353,302 shares of the biopharmaceutical company’s stock worth $16,387,000 after buying an additional 11,600 shares in the last quarter. Finally, AXA increased its holdings in Ultragenyx Pharmaceutical by 12.2% in the 3rd quarter. AXA now owns 265,408 shares of the biopharmaceutical company’s stock worth $14,136,000 after buying an additional 28,755 shares in the last quarter. Institutional investors own 87.19% of the company’s stock.



Shares of NASDAQ:RARE opened at $52.94 on Thursday. Ultragenyx Pharmaceutical has a 1-year low of $41.67 and a 1-year high of $71.99. The firm has a market cap of $2,612.74, a PE ratio of -7.06 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The firm had revenue of $2.41 million during the quarter, compared to analysts’ expectations of $0.75 million. During the same period in the previous year, the firm earned ($1.75) EPS. sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -6.03 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ultragenyx Pharmaceutical (RARE) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://dakotafinancialnews.com/2018/04/12/ultragenyx-pharmaceutical-rare-receives-consensus-recommendation-of-buy-from-brokerages.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply